Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6930822 | 0.83 | MAPT (0.48) | MAPTLMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL6474943 | 0.82 | HTR1A (0.59) | LMNAHTR1A | |
| SCHEMBL7609800 | 0.80 | HTR1A (0.50) | MAPTLMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8129784 | 0.79 | DRD2 (0.59) | HTR1A | |
| SCHEMBL11446928 | 0.79 | HTR1A (0.59) | LMNAALDH1A1POLBKMT2AHTR1A | |
| SCHEMBL6930821 | 0.74 | MAPT (0.48) | MAPTLMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL8013988 | 0.73 | DRD2 (0.63) | MAPTLMNAMAPK1ALDH1A1L3MBTL1 | |
| SCHEMBL13648743 | 0.72 | POLB (0.65) | MAPTLMNAMAPK1ALDH1A1TDP1 | |
| SCHEMBL7609804 | 0.72 | HTR1A (0.51) | MAPTLMNAMAPK1SMN1; SMN2ALDH1A1 | |
| SCHEMBL28219732 | 0.71 | MAPT (0.50) | MAPTLMNAMAPK1SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1000047-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | claimed |
| WO-1999006384-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | claimed |
| EP-1000047-B1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI CHEM PHARM (CH) | 2003-12-17 | — | — | EP | disclosed |
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMOANY | 2002-12-19 | — | — | US | disclosed |
| US-6399614-B1 | TREATING NEUROMUSCULAR DYSFUNCTION OF LOWER URINARY TRACT VIA PERIPHERAL OR CENTRAL NERVOUS SYSTEM; SEROTONIN RECEPTOR ANTAGONIST | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2002-06-04 | — | — | US | disclosed |
| US-6071920-A | BIND TO 5HT 1A RECEPTORS FOR TREATING DISORDERS OF THE LOWER URINARY TRACT; CNS DISORDERS; ANXIOLYTIC AGENTS; ANTIDEPRESSANTS; HYPOTENSIVE AGENTS; SLEEP AND EATING DISORDERS | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2000-06-06 | — | — | US | disclosed |
| EP-1000047-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006384-A1 | 1-(N-PHENYLAMINOALKYL)-PIPERAZINE DERIVATIVES SUBSTITUTED AT POSITION 2 OF THE PHENYL RING | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193383-A1 | 1-(N-phenylalkylaminoalkyl)piperazine derivatives substituted at position 2 of the phenyl ring | NLN, GLS, CPT1B | MAPT 2034/4885LMNA 2147/4885MAPK1 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.